Stramsen Biotech Clinches $25M Series B Funding to Propel Next-Generation Plant-Based Therapeutics

Stramsen Biotech, Inc., a groundbreaking Texas-based biopharmaceutical company that leverages a natural, plant-based approach, is excited to announce a recent funding milestone of $25,000,000. Incorporated in Delaware in November 2020 and now headquartered in Houston, Texas, this clinical-stage biotechnology firm is dedicated to developing innovative therapeutics to treat a range of infectious and noninfectious diseases, including cancer, COVID-19, HIV, and conditions related to cuts, wounds, and more. With access to an extensive database of over 8,000 medicinal plants, the company is uniquely positioned to harness nature’s potential in transforming patient care. The new capital injection will propel the advancement of several promising drug candidates currently under development, such as SBX 1052 for controlling prostate gland enlargement, SBX1968 and SBX2021 for mitigating the proliferation and metastasis of various cancers, and SBX 2022 targeted at blood cancer. Additional projects include SBX 2023 to treat peripheral neuropathic disorders, SBX 2000 for cardiovascular disease management, and SBX 1977, a potent wound-healing agent with antibacterial properties. Moreover, candidates like SBX 2048 aim to control HIV and boost immunity, while SBX1988 focuses on diabetes control, and SBX2011 is designed for kidney infections and gallstone dissolution. SBX1967, meanwhile, offers relief for bone and joint ailments while enhancing joint lubrication. This recent funding round underscores the strong investor confidence in Stramsen Biotech’s plant-based therapeutic approach. The funds will be strategically deployed to further bolster research and clinical trials, accelerating the company’s mission to harness nature’s healing properties and ultimately transform the lives of patients across the globe.